La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

JCR Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 5/6

JCR Pharmaceuticals ha un patrimonio netto totale di ¥55.7B e un debito totale di ¥28.2B, che porta il suo rapporto debito/patrimonio netto a 50.7%. Le sue attività totali e le sue passività totali sono rispettivamente ¥104.2B e ¥48.5B. L'EBIT di JCR Pharmaceuticals è ¥5.0B rendendo il suo rapporto di copertura degli interessi -66.1. Ha liquidità e investimenti a breve termine pari a ¥18.3B.

Informazioni chiave

50.7%

Rapporto debito/patrimonio netto

JP¥28.22b

Debito

Indice di copertura degli interessi	-66.1x
Contanti	JP¥18.34b
Patrimonio netto	JP¥55.67b
Totale passività	JP¥48.50b
Totale attività	JP¥104.17b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Aug 09

Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts

Aug 03

JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00

Jul 26

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

Jul 12

JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

May 22

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Mar 18

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

Feb 29

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ¥57.8B ) di 4552 superano le sue passività a breve termine ( ¥32.9B ).

Passività a lungo termine: Le attività a breve termine di 4552 ( ¥57.8B ) superano le sue passività a lungo termine ( ¥15.6B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 17.8% ) di 4552 è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di 4552 è aumentato da 17.9% a 50.7% negli ultimi 5 anni.

Copertura del debito: Il debito di 4552 è ben coperto dal flusso di cassa operativo ( 33% ).

Copertura degli interessi: 4552 matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.

JCR Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Investor sentiment deteriorates as stock falls 17%

Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts

First quarter 2025 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd Announces Discontinuation of TEMCELL HS Inj. Expanded Indication Development for Neonatal Hypoxic Ischemic Encephalopathy

JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

Final dividend of JP¥10.00 announced

MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB

Consensus EPS estimates fall by 17%

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024

Price target decreased by 10% to JP¥1,314

JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Investor sentiment deteriorates as stock falls 22%

Full year 2024 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 26, 2024

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2024, Payable on June 27, 2024

Upcoming dividend of JP¥10.00 per share

JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from FTSE All-World Index (USD)

JCR Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on May 10, 2024

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes

Now 22% overvalued

JCR Pharmaceuticals Co., Ltd. Presents Clinical Data on J-Brain Cargo®? to Deliver Medicines Across the Blood-Brain Barrier

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Price target decreased by 10% to JP¥1,657

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Jan 26, 2024

New major risk - Share price stability

JCR Pharmaceuticals Co., Ltd. Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

JCR Pharmaceuticals Co., Ltd. Declares Interim Dividend for the Fiscal Year Ending March 31, 2024, Payable on December 8, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

JCR Pharmaceuticals Co., Ltd. Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)

Upcoming dividend of JP¥10.00 per share at 1.5% yield

Investor sentiment improves as stock rises 18%

PHC IVD and JCR Announce GROWJECTOR® Duo

JCR Pharmaceuticals Co., Ltd. to Report Q2, 2024 Results on Oct 25, 2023

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Consensus EPS estimates increase by 13%

First quarter 2024 earnings released: EPS: JP¥12.90 (vs JP¥11.05 in 1Q 2023)

Price target decreased by 7.4% to JP¥1,859

JCR Receives Approval to Start Global Phase I/II Clinical Trial for JR-441 for the Treatment of Mucopolysaccharidosis Type III A (MPS IIIA)

Jcr Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Receives an Approval for Expanded Indication of Growject®? in Short Stature Due to SHOX-Deficiency

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 20%

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Jul 26, 2023

Consensus EPS estimates fall by 24%

Full year 2023 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 22, 2023

Investor sentiment deteriorates as stock falls 18%

Now 21% undervalued after recent price drop

Consensus revenue estimates fall by 17%

Upcoming dividend of JP¥10.00 per share at 1.3% yield

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

JCR Pharmaceuticals Co., Ltd. to Present Phase I/II Clinical Data on JR-171

Third quarter 2023 earnings released: EPS: JP¥20.89 (vs JP¥29.79 in 3Q 2022)

U.S. Fda Grants Rare Pediatric Disease Designation for JCR Pharmaceuticals Co., Ltd. Jr-141 for Mpsii

JCR Pharmaceuticals Co., Ltd. Appoints Yoh Ito as Senior Corporate Officer

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Announces Interim Dividend Payable on December 9, 2022; Provided Dividend Guidance for Fiscal 2023

Now 20% undervalued after recent price drop

JCR to Initiate Development of New Drug Candidate for Fucosidosis

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. Announces Interim Dividend on Retained Earnings, Payable on December 9, 2022

Price target decreased to JP¥2,861

Now 21% undervalued after recent price drop

Upcoming dividend of JP¥10.00 per share

Jcr Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

JCR Pharmaceuticals Co., Ltd. Announces Update on Application for Manufacturing and Marketing Approval of JR-141 for Treatment of MPS II (Hunter Syndrome) in Brazil